Compare RLX Technology Inc (RLX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
RLX Technology Inc vs Viatris Inc — how do they compare? RLX Technology Inc trades at $1.77 (market cap $2.15B), while Viatris Inc trades at $16.5 (market cap $18.95B). The key difference: Viatris Inc is far larger — about 8.8× RLX Technology Inc's market cap, and RLX Technology Inc pays the higher dividend (5.68%). Which is the better fit depends on your goals.
| RLX | VTRS | |
|---|---|---|
Market Cap | $2.15B | $18.95B |
Sector | Technology | Health |
52-Week High | $2.69 | $17.86 |
52-Week Low | $1.76 | $9.49 |
Enterprise Value | $882.29M | $31.07B |
Dividend Yield | 5.68% | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RLX trades at $1.79, down 0.56% on the day, with a bearish technical signal driven by moving averages and a neutral RSI. The company reported Q2 2026 revenue growth of 14.8% year-over-year, supported by international expansion, but missed EPS estimates for three consecutive quarters. Profitability remains solid with a net income margin of 21.87% and a P/E ratio of 15.83, indicating reasonable valuation.
The outlook is mixed; international growth offers upside, but consistent earnings misses and a single hold rating from analysts suggest caution. Key risks include regulatory pressures in the e-vapor industry and execution challenges in European integration. Investors should weigh growth potential against near-term volatility and sentiment headwinds.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
